Monoclonal Anti-Influenza Virus Neuraminidase (NA) Recombinant Human Antibody, Clone 1G01 (produced in Expi293F cells)

Catalog No. NR-55886

For research use only. Not for use in humans.

Contributor:
Ali Ellebedy, Ph.D., Associate Professor, Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Missouri, USA

Manufacturer:
BEI Resources

Product Description:
NR-55886 is a monoclonal anti-influenza virus neuraminidase (NA) recombinant human antibody, clone 1G01 produced in Expi293F cells by transfection of plasmids expressing corresponding immunoglobulin heavy and light chains. The antibody was purified by protein G chromatography.

Recombinant human monoclonal antibody 1G01 was produced by cloning the corresponding immunoglobulin heavy and light chains from a single plasmablast sorted from the PBMCs of an H3N2 infected donor.[1] The antibody heavy and light chain variable region sequences are available (Genbank: MN013068 and MN013072, respectively).[1,2] 1G01 recognizes NAs from influenza A group 1 (N1, N4, N5, N8), group 2 (N2, N3, N6, N7, N9) and influenza B viruses.[1,2]

Material Provided:
Each vial of NR-55886 contains approximately 500 µL of purified monoclonal antibody in phosphate-buffered saline (PBS; pH 7.4). The concentration, expressed as milligrams per milliliter, is shown on the Certificate of Analysis.

Packaging/Storage:
NR-55886 was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. The product should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Citation:
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Monoclonal Anti-Influenza Virus Neuraminidase (NA) Recombinant Human Antibody, Clone 1G01 (produced in Expi293F cells), NR-55886."

Biosafety Level: 1
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:
You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:
This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:
1. Ellebedy, A., et al., Personal Communication.
2. Stadlbauer, D., et al. "Broadly Protective Human Antibodies that Target the Active Site of Influenza Virus Neuraminidase." Science 366 (2019): 499-504. PubMed: 31649200.

ATCC® is a trademark of the American Type Culture Collection.

Support Provided by NIAID